Out-of-pocket costs continue to increase for patients who must buy commonly prescribed drugs to treat these five neurological ...

Data from the SENZA-PDN trial showed 10 kHz SCS yielded long-term, clinically meaningful reductions in HbA1c and weight in patients with PDN and T2D.

The amount of money people pay out-of-pocket for branded drugs to treat neurological diseases like multiple sclerosis (MS), Alzheimer's, and Parkinson's disease continues to rise, especially for MS ...

Harvard Medical School has said out that a tingling sensation in the feet could be a sign of a vitamin B12 deficiency. It ...

In addition, these factors also stimulate inflammation-related damage to the nervous system, contributing to ...

Vitamins and mineral supplements can help address nutritional deficiencies that commonly affect people who have Crohn’s ...

Living with a chronic pain condition can make everyday tasks more challenging. For some people in Southern Utah dealing with ...

The Bcl-2 inhibitor venetoclax is highly effective and is another first- or second-line option even if this agent, like BTK inhibitors, also appears to require continuous dosing, said Stadtmauer, ...

Suneeta’s research centers on identifying novel molecular signatures and biomarkers to improve the efficacy of cancer ...

New data will showcase significantly increased and sustained minimal residual disease (MRD) negativity rates, reinforcing the potential of ...

Jiangsu Alicorn Pharmaceutical Co. Ltd. has described AP2-associated protein kinase 1 (AAK1) inhibitors reported to be useful for the treatment of Alzheimer’s disease, bipolar disorder, Parkinson’s ...

In this case report, Gad and colleagues performed corneal confocal microscopy to assess for evidence of nerve regeneration ...